Compare WEST & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WEST | TBPH |
|---|---|---|
| Founded | 2009 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 812.3M | 908.9M |
| IPO Year | 2022 | 2013 |
| Metric | WEST | TBPH |
|---|---|---|
| Price | $8.18 | $17.05 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 6 |
| Target Price | $7.00 | ★ $18.40 |
| AVG Volume (30 Days) | 238.6K | ★ 365.5K |
| Earning Date | 05-07-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 279.13 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,188,952,000.00 | $15,386,000.00 |
| Revenue This Year | $11.27 | $8.46 |
| Revenue Next Year | $10.66 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 39.76 | N/A |
| 52 Week Low | $3.59 | $13.08 |
| 52 Week High | $10.19 | $21.03 |
| Indicator | WEST | TBPH |
|---|---|---|
| Relative Strength Index (RSI) | 53.31 | 57.96 |
| Support Level | $7.65 | $16.80 |
| Resistance Level | $8.58 | $17.11 |
| Average True Range (ATR) | 0.28 | 0.05 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 75.00 | 21.57 |
Westrock Coffee Co is an integrated coffee, tea, flavors, extracts, and ingredients solutions provider mainly in the United States. Additionally, it offers coffee sourcing, supply chain management, product development, roasting, packaging, and distribution services to retail, foodservice, restaurant, convenience store, travel center, non-commercial account, and hospitality industries around the world. The company's reportable segments are: Beverage Solutions and Sustainable Sourcing and Traceability. It generates maximum revenue from the Beverage Solutions segment, which offers beverage solutions, including coffee, tea, flavors, extracts, and ingredients. Geographically, the company generates maximum revenue from its business in the United States and the rest from other countries.
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.